MARKET

OCUL

OCUL

Ocular
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.920
+0.040
+0.82%
After Hours: 4.920 0 0.00% 16:00 03/27 EDT
OPEN
4.670
PREV CLOSE
4.880
HIGH
5.19
LOW
4.660
VOLUME
641.20K
TURNOVER
--
52 WEEK HIGH
8.12
52 WEEK LOW
2.350
MARKET CAP
258.68M
P/E (TTM)
-2.5802
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of OCUL and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average OCUL stock price target is 9.00 with a high estimate of 15.00 and a low estimate of 3.000.

EPS

OCUL News

More
  • Daily Insider Ratings Round-Up 3/24/20
  • Seeking Alpha - Article · 3d ago
  • Daily Insider Ratings Round Up + Daily Ratings Report For 3/20/20
  • Seeking Alpha - Article · 03/22 17:35
  • Daily Insider Ratings Round Up 3/17/20
  • Seeking Alpha - Article · 03/18 23:50
  • Jefferies Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces $8 Price Target
  • Benzinga · 03/17 14:22

Industry

Medical Equipment, Supplies & Distribution
-1.60%
Healthcare Equipment & Supplies
-1.86%

Hot Stocks

Symbol
Price
%Change

About OCUL

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.
More

Webull offers kinds of Ocular Therapeutix Inc stock information, including NASDAQ:OCUL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUL stock news, and many more online research tools to help you make informed decisions.